Drugs / TE-8214
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06372652 | Jun → Oct 2024 | acromegaly | Immunwork, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-08-27 | Immunwork, Inc. | Results Immunwork’s Next-Generation Long-Acting Octreotide Analog TE-8214 Published in International Journal immunwork.com ↗
The publication presents the innovative drug design and nonclinical findings of TE-8214, together with clinical findings from its first-in-human study, including safety, tolerability, and therapeutic potential, providing an important scientific foundation for its continued clinical development. |
| 2025-07-01 | Immunwork, Inc. | Results Immunwork Announces Positive Phase I Top-Line Data for TE-8214, a Long-Acting Octreotide, Demonstrating Favorable Safety, Tolerability, and Potent IGF-1 Suppression immunwork.com ↗
Immunwork, Inc., a clinical-stage biotechnology company developing transformative therapies, today announced positive top-line results from its Phase I clinical trial (in Australia) of TE-8214, a novel long-acting octreotide analog for the treatment of acromegaly and neuroendocrine tumors (NETs). |
| 2024-07-30 | Immunwork, Inc. | Results Two ultra-long acting drugs receive promising news! Phase 1 clinical trials are expected to be completed next year! immunwork.com ↗
Both drugs have undergone initial dosing in low-dose subjects, showing good tolerance and no significant side effects. |
All press releases naming this drug 4 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TE-8214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06372652 ↗ |